Androgenetic Alopecia Clinical Trial
Official title:
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
Verified date | October 2020 |
Source | Icahn School of Medicine at Mount Sinai |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the clinical efficacy of platelet rich plasma (PRP) injections for non-scaring alopecia in women. A randomized, placebo-controlled clinical trial will be performed where patients with non-scarring alopecia will either receive injections of their own PRP or injections of normal saline (placebo). Patients in the treatment group (Group A) will have a small amount of their own blood drawn and have their PRP injected into their scalp four times. The injections will be given at weeks zero, four, eight, and twenty four. The placebo group (Group B) will be given the same schedule but will receive sham injections only and will not have any blood drawn. Both groups will have clinical data collected at all visits, including a screening visit before enrollment and a final assessment visit at week 40, for a total of 6 study visits per patient. Data collection will include representative photographs of the scalp and measurements of hair thickness. The results from the two groups will then be compared. In summary, all study participants will have a screening visit before enrollment, four study visits for sub-dermal scalp injections, and one final assessment visit at week 40.
Status | Completed |
Enrollment | 30 |
Est. completion date | June 3, 2019 |
Est. primary completion date | June 3, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Must understand and voluntarily sign an informed consent form 2. Must be female between the ages of 18 and 65 years at the time of consent 3. Must be able to adhere to the study visit schedule and other protocol requirements 4. Documented platelet count above 150,000 platelets per microliter within 6 months prior to enrollment Exclusion Criteria: 1. Previous or current use in the last 1 year of finasteride, minoxidil topical or oral, or spironolactone 2. A diagnosis of non-androgenic alopecia (i.e: another diagnosis for the alopecia ) 3. No Baseline ferritin, thyroid-stimulating hormone, platelet count, and a negative urine pregnancy test in any pre-menopausal female in past 12 months. 4. Active skin disease (Psoriasis or severe seborrheic dermatitis) of the scalp 5. Scalp infection 6. Severe active blood infection 7. Cuts or abrasions on the scalp 8. History of surgical hair restoration 9. Current or recent malignancy 10. History of systemic chemotherapy or radiation 11. History of thyroid dysfunction 12. History of autoimmune disorder (specifically Graves disease, hashimoto thyroiditis, or systemic lupus erythematosus) 13. Tendency to develop keloids 14. Nonsteroidal anti-inflammatory or Vitamin E discontinued in the last 7-14 days 15. Platelet dysfunction syndrome 16. Thrombocytopenia less than 150,000 17. Diagnosis of hypofibrinogenemia 18. Anticipated pregnancy or trying to become pregnant in the next 2 years |
Country | Name | City | State |
---|---|---|---|
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai | Eclipse Aesthetics, LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Improvement | Number of participants with improvement by qualitative global assessment of hair growth using photography. Photographs of the scalp with standard digital camera used to assess overall change in hair appearance on a macroscopic level. This will be done using the Ludwig Classification system.
I is appreciable thinning of the crown hair, II is increased territorial involvement and scalp visibility, and III is total denudation of the areas involved in I and II |
through study completion, 24 weeks | |
Primary | Change in Hair Caliber Using Trichoscopy | Change in Hair Caliber using trichoscopy as compared to baseline. Trichoscopy is a microscope used to assess hair. This was used to measure hair caliber in millimeters. | Week 8 and 24 | |
Primary | Change in Hair Density Using Trichoscopy | Change in Hair Density using trichoscopy as compared to baseline. Trichoscopy is a microscope used to assess hair. This was used to measure hair density (number of hairs in a square centimeter of scalp). | Week 8 and 24 | |
Secondary | Qualitative Assessment of Hair Growth | Surveys will be distributed to assess participant opinion regarding overall hair growth after treatment. This will be done using a hair growth scale in which 0 is no improvement in hair growth and 10 is greatly improved hair growth. | Week 40 | |
Secondary | Qualitative Assessment of Pain Associated With the Treatment | Surveys will be distributed to assess participant opinion regarding the degree of pain associated with the treatment. This will be done using a pain scale of 0 to 10 with 0 being no pain and 10 being worst pain ever. | Week 40 | |
Secondary | Qualitative Assessment of Adverse Effects Associated With the Treatment | Questionnaires will be distributed to assess participant opinion regarding adverse effects associated with the treatment. This will be assessed via a multiple choice questionnaire with the following options:
i. Headache ii. Scalp tightness iii. Swelling iv. Redness v. Post-injection bleeding vi. Infection vii. Nerve damage viii. Other: ____________________ ix. None |
Week 40 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02591355 -
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
|
N/A | |
Withdrawn |
NCT03852992 -
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
|
Phase 2 | |
Recruiting |
NCT06239207 -
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT04945226 -
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
|
Phase 1/Phase 2 | |
Completed |
NCT01548066 -
The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss
|
Phase 2 | |
Completed |
NCT01437163 -
Treatment of Androgenetic Alopecia in Males and Females
|
N/A | |
Completed |
NCT01226459 -
Clinical Trial in Females for Female Pattern Hair Loss
|
Phase 3 | |
Recruiting |
NCT06118866 -
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT06149221 -
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
|
N/A | |
Withdrawn |
NCT04882969 -
Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia
|
N/A | |
Completed |
NCT01231607 -
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
|
Phase 3 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT02729415 -
Point-of-Care Adipose-derived Cells for Hair Growth
|
N/A | |
Completed |
NCT02279823 -
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
|
Phase 2 | |
Not yet recruiting |
NCT01227031 -
Pharmacogenomic Study of Androgenetic Alopecia
|
N/A | |
Completed |
NCT00981461 -
Treatment of Androgenetic Alopecia in Females, 9 Beam
|
N/A | |
Completed |
NCT01451021 -
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
|
Phase 2 | |
Completed |
NCT00151515 -
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
|
Phase 3 | |
Completed |
NCT03694067 -
Androgenetic Alopecia and the JAK-STAT Pathway
|
||
Completed |
NCT03753113 -
Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
|
Phase 3 |